NEAM
AZN icon

New England Asset Management’s AstraZeneca AZN Stock Holding History

New England Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,186
Closed -$252K – 171
2018
Q3 		$252K Hold
3,186
– – ﹤0.01% 176
2018
Q2 		$224K Buy
+3,186
New +$229K ﹤0.01% 176

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

New England Asset Management's AZN Position: Q4 2018 in Review

New England Asset Management sold out of AstraZeneca (AZN) in Q4 2018, closing a stake of 3,186 shares — an estimated $252K sold.

New England Asset Management first reported a position in AZN in Q2 2018 and held it in 2 quarters. The position peaked at $252K in Q3 2018. 557 funds tracked by Wall St. Rank hold AZN as of Q4 2018.

  • New England Asset Management reported no remaining AstraZeneca position as of Q4 2018 after selling out during the quarter.
  • New England Asset Management sold 3,186 AstraZeneca shares in Q4 2018, an estimated $252K.
  • New England Asset Management first reported a position in AstraZeneca in Q2 2018 and held it in 2 quarters.
  • New England Asset Management's AstraZeneca position peaked at $252K in Q3 2018.
  • 557 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2018.

Based on New England Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.